Dr Jorge Cortes speaks to ecancer about a study he presented at the virtual ASH 2020 meeting on the use of the first-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation.
He reports the 52 patients treated had an MMR rate of 47%, with patients previously treated with ponatinib fairing worse than those that had not been.
Dr Cortes believes that the results show a very active drug in this context with good responses even in ponatinib treated patients.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.